Adipokines and C-peptide in overweight and obese pregnant women. 2018

Elżbieta Poniedziałek-Czajkowska, and Radzisław Mierzyński, and Magdalena Słodzińska, and Dominik Dłuski, and Bożena Leszczyńska-Gorzelak

The aim of the study was to evaluate the levels of adipokines such as adiponectin, resistin, leptin as well as C-peptide in overweight and obese pregnant women. The adipokines and C-peptide concentrations were measured in the group of 38 overweight/obese pregnant women (BMI > 25 kg/m2) and in 42 pregnant women of normal weight (BMI < 25 kg/m2) with ELISA tests between 24th and 34th weeks of gestation. The overweight/obese women compared to lean ones were characterized by significantly higher concentrations of leptin (43.44 ± 31.41 vs. 21.29 ± 12.67 ng/mL, p = 0.0001) and C-peptide (2.77 ± 1.88 vs. 2.25 ± 1.42 ng/mL, p = 0.034). There were no significant differences between groups in resistin (17.39 ± 7.59 vs. 15.76 ± 6.64 ng/mL, NS) and adiponectin (6.93 ± 3.52 vs. 8.07 ± 6.53 μg/mL, NS) levels. In the overweight/obese patients, no relationships between the adipokines, C-peptide and CRP concentrations were found. BMI was negatively correlated with the resistin levels (R = -0.406, p = 0.011). The significant correlation between leptin and C-peptide concentrations was observed in the study group (R = 0.517, p = 0.012). In the control group, the negative correlation between adiponectin concentrations and BMI was shown (R = -0.446, p = 0.003). The higher levels of leptin in the overweight and obese pregnant women seem to reflect the leptin resistance condition and the higher levels of C-peptide in this group is suggestive for hyperinsulinemia. The positive correlation between C-peptide and leptin levels but not with resistin and adiponectin might confirm the role of leptin in the hyperinsulinemia development in overweight and obesity during pregnancy.

UI MeSH Term Description Entries
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011248 Pregnancy Complications Conditions or pathological processes associated with pregnancy. They can occur during or after pregnancy, and range from minor discomforts to serious diseases that require medical interventions. They include diseases in pregnant females, and pregnancies in females with diseases. Adverse Birth Outcomes,Complications, Pregnancy,Adverse Birth Outcome,Birth Outcome, Adverse,Complication, Pregnancy,Outcome, Adverse Birth,Pregnancy Complication
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D015854 Up-Regulation A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Up-Regulation,Upregulation,Up-Regulation (Physiology),Up Regulation
D015992 Body Mass Index An indicator of body density as determined by the relationship of BODY WEIGHT to BODY HEIGHT. BMI Quetelet Index,Quetelet's Index,Index, Body Mass,Index, Quetelet,Quetelets Index

Related Publications

Elżbieta Poniedziałek-Czajkowska, and Radzisław Mierzyński, and Magdalena Słodzińska, and Dominik Dłuski, and Bożena Leszczyńska-Gorzelak
August 2010, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego,
Elżbieta Poniedziałek-Czajkowska, and Radzisław Mierzyński, and Magdalena Słodzińska, and Dominik Dłuski, and Bożena Leszczyńska-Gorzelak
January 2010, Neuro endocrinology letters,
Elżbieta Poniedziałek-Czajkowska, and Radzisław Mierzyński, and Magdalena Słodzińska, and Dominik Dłuski, and Bożena Leszczyńska-Gorzelak
December 2017, Purinergic signalling,
Elżbieta Poniedziałek-Czajkowska, and Radzisław Mierzyński, and Magdalena Słodzińska, and Dominik Dłuski, and Bożena Leszczyńska-Gorzelak
March 2024, International journal of molecular sciences,
Elżbieta Poniedziałek-Czajkowska, and Radzisław Mierzyński, and Magdalena Słodzińska, and Dominik Dłuski, and Bożena Leszczyńska-Gorzelak
May 2018, Endocrine journal,
Elżbieta Poniedziałek-Czajkowska, and Radzisław Mierzyński, and Magdalena Słodzińska, and Dominik Dłuski, and Bożena Leszczyńska-Gorzelak
January 2014, Gynecologie, obstetrique & fertilite,
Elżbieta Poniedziałek-Czajkowska, and Radzisław Mierzyński, and Magdalena Słodzińska, and Dominik Dłuski, and Bożena Leszczyńska-Gorzelak
June 2009, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie,
Elżbieta Poniedziałek-Czajkowska, and Radzisław Mierzyński, and Magdalena Słodzińska, and Dominik Dłuski, and Bożena Leszczyńska-Gorzelak
January 2016, PloS one,
Elżbieta Poniedziałek-Czajkowska, and Radzisław Mierzyński, and Magdalena Słodzińska, and Dominik Dłuski, and Bożena Leszczyńska-Gorzelak
August 2019, Clinical nutrition (Edinburgh, Scotland),
Elżbieta Poniedziałek-Czajkowska, and Radzisław Mierzyński, and Magdalena Słodzińska, and Dominik Dłuski, and Bożena Leszczyńska-Gorzelak
June 2009, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology,
Copied contents to your clipboard!